Rocio Camacho

Gran sede y excelente formación en Hematología. Ahora trabajando en Europa, puedo decir que el nivel y la exigencia están totalmente a altura internacional. 👩🏻‍⚕️🩸✨

Glad to share our @Yale tour-de-force review of #MDSsm published in @Nature Reviews of Clinical Oncology (Free online read at rdcu.be/fdl9e) which has to be the most comprehensive review we have ever written on the subject covering all relevant areas from epidemiology, pathogenesis, diagnosis, risk stratification, to current and evolving therapies for lower and higher risk disease @YaleCancer @YaleHematology @YaleMed

Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts—what truly defines the disease and does it matter? Our @TheEBMT Viewpoint Made the cover page of @TheLancetHaem Thanks so much @DrLornan and Fernando Barroso Duarte @SBTMO #closeFullCover" target="_blank" rel="nofollow noopener">thelancet.com/issue/S2352-30…

🔥Just in time for #ASH25, our open access paper @AjHematology on why we DON'T routinely recommend treatment in high-risk SMM (yet) is now online! @MorieGertz tinyurl.com/mrxa7tde I encourage patients & trainees to listen to the best arguments on both sides of the debate!

@plasmablasto Para 130 millones de habitantes 🥲

Pensé que éramos más 🫨

Alfred Nobel at EHA @EHA2026 @EHA_Hematology

The cells you see on a bone marrow aspirate 👇🏼 #MedTwitter doi.org/10.1038/s41598…

Sistema de clasificación armonizado y basado en datos en SMD ➡️Consorcio Internacional SMD 📍En 2022 salieron las 2 clasificaciones para MDS: WHO e ICC ✅Algoritmo propuesto por consorcio para unificar clasificaciones de manera jerárquica doi: 10.1016/ S2352-3026(24)00251-5

All what you needed to know about hairy cell leukemia. A comprehensive review published in the ⁦@NEJM⁩ ⁦@TheIACH⁩

@Indie5051 @AlexBrr 🤭

México Surrealista 🇲🇽 Metallica acaba de tocar "La Chona", de los Tucanes de Tijuana, en Ciudad de México. 📸 Julia Muñoz

RELATIVE SIZES OF BLOOD CELLS I asked ChatGPT to draw relative sizes of RBCs, WBCs and platelets, and it came up with this image (check out the platelets imbedded in the WBC). So cool!

#Hemepath 101 Burkitt lymphoma (in bone marrow) Starry sky 🌌… medium cells, no nucleoli MYC-rearranged (IHC: overexpression) Ki67 ~100% BCL2 negative

Immunology, made simple...

@astridhdlt @hospitalclinic 🔝 🔝 🔝 muchas felicidades!! Lo harás increíble Astrid 💪🏻

Oficialmente inicia una nueva aventura en el @hospitalclinic y no puedo estar más emocionada! ☺️☺️☺️☺️

@GvHD_Meade @rajuan_27 @ContactoAmeh Excelente vista para estudiar 📚

@RocioCamachoMD @rajuan_27 @ContactoAmeh El Ajusco definitivamente imparte carácter a la imagen 👍

Lymphoma Saturday! 👩🏻‍💻📚✨Today learning from my dear friend and top lymphoma doctor @rajuan_27 at @ContactoAmeh 👏🏼

1/🚨NEW #GrayMatters segment on iron deficiency🚨 Note: we didn’t say “iron deficiency anemia”! Anemia is the FINAL STATE, not an early marker! 🎧: link.chtbl.com/FeDef 🖥️: bit.ly/4aaMLnz ACP CME: bit.ly/CIMCME Sponsor: coreimpodcast.com/Freed

KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). Read the news release: kdigo.co/CKD-Guideline-… Download the guideline: kdigo.co/2024-CKD-Guide… Read the guideline in Kidney International: kdigo.co/CKD-Guideline-… The KDIGO 2024 CKD Guideline was co-chaired by @adeeralevin and @KidneysRU. The Executive Summary will be published in the April 2024 issue of @Kidney_Int. “We are thrilled to publish this eagerly anticipated update, which comes during a transformative period in nephrology, offering new hope for people living with kidney disease," said Dr. Levin. “Recent advancements in GFR evaluation, risk prediction, and the arrival of novel treatments are poised to enhance CKD prognosis and management. We also hope the guideline’s emphasis on multidisciplinary teamwork, patient engagement, and a holistic, evidence-based approach to care will help catalyze positive change, resulting in more coordinated CKD care management worldwide. By integrating the latest evidence and expert consensus, we aim to empower healthcare professionals, and patients with actionable recommendations to optimize patient outcomes and enhance quality of life.” “As Co-Chairs, we would like to recognize the outstanding efforts of the Guideline Work Group and extend our thanks to the Evidence Review Team from Johns Hopkins, without whom this guideline would not have been possible," said Dr. Stevens. "The Work Group was diverse, multinational, highly experienced, and exceptionally committed, and we are grateful for their contributions to both this guideline and to global nephrology.”

Mechanism of daratumumab interference with the indirect antiglobulin test (IAT). Positive IAT due to interference from daratumumab, which binds to CD38 on RBCs and causes agglutination with the addition of Coombs reagent #mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS

19 yr pt. Dx of CML, stopped imatinib 2 yr ago. WBC 228000. PB: 24% myeloid blasts, 30% baso. PCR BCR::ABL+, no ABL muts. Cg: t(9;22) & inv(16). How would you treat? @Anand_88_Patel @CanerSaygin @DrWendyStock @RobertaDemiche3 @wellingtonhemat @Dr_AmerZeidan @PratzKW @GCC_Cortes